A breakthrough CAR-T cell therapy, Qartemi, has been approved for blood cancer patients in India, offering new hope to those ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the ...

Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, ...

A study of 783 patients treated with CAR T cell therapy found no evidence that the therapy itself caused secondary cancers.

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Tim Orth Memorial Foundation basketball jamboree is Saturday in Glencoe, and as usual all proceeds from that night will go to help kids and their families with medical bills. This ...

January's FDA oncology approvals offer new treatment options for breast cancer, mantle cell lymphoma, and other malignancies.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a REMS, highlighting its safety and unique mechanism.

A new computational tool could help researchers identify promising drug combinations for treating cancer, according to a new study.

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...